Walleye Capital
CYT

Walleye Capital’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Walleye Capital’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-427,037
Closed -$1.3M – 6094
2023
Q4 		$1.3M Buy
427,037
+73,121
+21% +$222K ﹤0.01% 2144
2023
Q3 		$1.01M Buy
+353,916
New +$975K ﹤0.01% 2244

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Walleye Capital's CYT Position: Q1 2024 in Review

Walleye Capital sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 427,037 shares — an estimated $1.3M sold.

Walleye Capital first reported a position in CYT in Q3 2023 and held it in 2 quarters. The position peaked at $1.3M in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Walleye Capital reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 427,037 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.3M.
  • Walleye Capital first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Walleye Capital's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.3M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.